- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07645222
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
A PHASE Ib STUDY OF THE SAFETY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY OF HS-20122 COMBINED THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Guangdong
-
Guangzhou, Guangdong, Chine
- Recrutement
- Ethics Committee of Sun Yat-sen University Cancer Center
-
Contact:
- Ran Xu, MD
- Numéro de téléphone: 86-20-87343009
- E-mail: llwyh@sysucc.org.cn
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Locally advanced or metastastic NSCLC;
- Received at least 1 line SoC,or treatment naïve;
- With at least 1 target lesion according to RECIST 1.1.
- Appropriate organ function
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1 and no deterioration within 2 weeks prior to the first dose.
- Minimum expected survival longer than 12 weeks
- Female subjects of childbearing potential are willing to take appropriate contraceptive measures and should not breastfeed from signing the informed consent form (ICF) through 6 months after the last dose; male subjects are willing to use barrier contraception (i.e., condom) from signing the ICF through 6 months after the last dose.
- Voluntarily participate in this clinical trial, understand the study procedures, and be able to sign written informed consent form.
Exclusion Criteria:
- Insufficient wash out duration of prior systemic anticancer therapy
- Local radiotherapy within 2 weeks prior to first dose of investigational drug
- Pleural/abdominal effusion requires clinical intervention
- Major surgery within 4 weeks prior to first dose of investigational drug
- History of drugs may prolong QT interval
- Have any grade ≥ 2 residual toxicity according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) from prior anti-tumor therapy (except alopecia and residual neurotoxicity).
- Presence of brain metastasis or carcinomatous meningtitis
- History of other primary malignancies
- Significant, uncontrolled, or active cardiovascular diseases
- Severe or poorly controlled diabetes
- Extremely obesity or emaciation
- Clinically significant bleeding symptoms or obvious bleeding tendency within 1 month prior to the first dose
- Severe arteriovenous thrombotic events (e.g., deep venous thrombosis, pulmonary embolism) within 3 months prior to the first dose
- Severe infection within 4 weeks
- History of systemic glucocorticoids over 28 days prior to first dose of investigational drug
- Presence of known active infectious diseases,
- Prensence of ophthalmological abnormalities.
17.Presence of hepatic encephalopathy, Hepato-renal Syndrome 18.Presence or history of confirmed or suspected ILD; 19.Prior history of significant neurological or mental disorders, including conditions that interfere with assessment, such as epilepsy, dementia, or major depressive disorder.
20.History of severe allergy, or history of hypersensitivity to any active or inactive ingredient of investigational drugs.
21.Presence of any conditions that jeopardize subject safety or interfere with study assessments as judged by the investigator.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: HS-20122+Aumolertinib
|
EGFR mut NSCLC, receive HS-20122+Aumolertinib
|
|
Expérimental: HS-20122+Adbrelimab
|
EGFRwt NSCLC,receive HS-20122+Adbrelimab
|
|
Expérimental: HS-20122+Adbrelimab+Platinum-based Chemo
|
EGFR wt NSCLC,receive HS-20122+Adbrelimab+ Platinum-based Chemo
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Événement indésirable grave
Délai: Pendant toute la durée de cet essai, soit environ 2 ans
|
incidence des événements indésirables graves évalués par l'investigateur, classés selon CTCAE V5.0
|
Pendant toute la durée de cet essai, soit environ 2 ans
|
|
RP2D for Combination
Délai: Through the full duration of this trial, approximately 2 years
|
To evaluate the potent and tolerated of combination(s) and dosage(s) of HS-20122 based therapy in subjects with locally advanced or metastatic NSCLC who have experienced disease progression on or after prior treatment, which suitable for a Phase II trial
|
Through the full duration of this trial, approximately 2 years
|
|
ORR
Délai: Through the full duration of this trial, approximately 2 years;
|
Investigator evaluated overall response rate, to evaluate the efficacy of each combination;
|
Through the full duration of this trial, approximately 2 years;
|
|
TEAE
Délai: Through the full duration of this trial, approximately 2 years;
|
incidence of Investigator evaluated Treatment Emerged Adverse Events, graded per CTCAE V5.0
|
Through the full duration of this trial, approximately 2 years;
|
|
TRAE
Délai: Through the full duration of this trial, approximately 2 years;
|
incidence of Investigator evaluated Treatment Related Adverse Events, graded per CTCAE V5.0
|
Through the full duration of this trial, approximately 2 years;
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Duration of Response
Délai: Through the full duration of this trial ,approximately 2 years
|
Investigator evaluated Duration of Response
|
Through the full duration of this trial ,approximately 2 years
|
|
Disease Control Rate
Délai: Through the full duration of this trial ,approximately 2 years;
|
Investigator evaluated Disease Control Rate
|
Through the full duration of this trial ,approximately 2 years;
|
|
Progression Free Survival
Délai: Through the full duration of this trial, approximately 2 years;
|
Investigator evaluated duration of Progression Free Survival
|
Through the full duration of this trial, approximately 2 years;
|
|
Overall Survival
Délai: Through the full duration of this trial ,approximately 2 years;
|
Investigator evaluated duration of Overall Survival
|
Through the full duration of this trial ,approximately 2 years;
|
|
PK parameter
Délai: Through the full duration of this trial, approximately 2 years;
|
blood concentration of combo agents
|
Through the full duration of this trial, approximately 2 years;
|
|
Immuogencity
Délai: Through the full duration of this trial ,approximately 2 years;
|
positive rate of drug specific antibody
|
Through the full duration of this trial ,approximately 2 years;
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- HS-20122-103
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .